Clinical Trials Logo

Antibody-mediated Rejection clinical trials

View clinical trials related to Antibody-mediated Rejection.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03805178 Withdrawn - Clinical trials for Lung Transplant Rejection

Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization

Start date: May 1, 2019
Phase: Phase 2
Study type: Interventional

Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes after lung transplantation. Additionally, high antibodies detected pre transplant in candidates limit donor availability for lung transplant. This proposal would include belatacept in a multi-therapy regimen. Open label study with two patient cohorts for safety and efficacy of belatacept in a multi-modal protocol. The two patient cohorts are an AMR post-transplant cohort and pre-transplant desensitization cohort. A total of 10 patients will be enrolled.The primary objection is drug tolerability and secondary objectives are antibody measurements and allograft function.

NCT ID: NCT02130817 Withdrawn - Clinical trials for End Stage Renal Disease

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

BelatPilot
Start date: September 24, 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a standard of care regimen of immunosuppressive medications and plasma exchange (plasmapheresis and immunoglobulin treatment) for kidney transplant patients who are moderately sensitized against their deceased donor and at-risk for delayed graft function. The hypothesis is that moderately sensitized patients who receive Belatacept treatment with the standard of care regimen will lead to lower acute rejection rates than historical controls based on assessment of standard of care biopsies and standard Banff criteria.